TORONTO, Ontario (PRWEB) February 20, 2020 -- In a free session on Tuesday, March 10, 2020 at 11am EDT (3pm GMT/UK) join guest speakers from Synteract including Lisa Dilworth, BS, MS, Vice President Rare, Orphan and Pediatric Diseases, and Rachael Young, Associate Director, Feasibility for a discussion about these challenges, with feasible strategies and solutions to support patients, sites and sponsors.
When planning a rare disease clinical trial, drug developers can expect to face several challenges. In many cases, developers approach the study believing that patient recruitment will be their biggest obstacle. They are correct in making this assumption, but it is not always for the reasons they assumed.
Finding patients is, in fact, the most common obstacle experienced in rare disease clinical trials. Nevertheless, it is not always due to lack of patient presence, rather it is the culmination of several key challenges. This includes but is not limited to understanding the diagnostic odyssey, competitive study and treatment landscape, ability to operationalize at the global, regional and site level. This is where a robust, data-driven feasibility analysis becomes a necessary, key component.
For more information or to register for this event, visit Assessing the Competition in Rare Disease Clinical Trials: The Need for a Thorough Feasibility Strategy.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Mira Nabulsi, Xtalks, http://www.xtalks.com, +1 (416) 977-6555 x 400, [email protected]